Molindone
 | |
|---|---|
| Systematic (IUPAC) name | |
| 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)- 1,5,6,7-tetrahydro-4H-indol-4-one | |
| Clinical data | |
| Trade names | Moban |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a682238 |
| Pregnancy cat. | C |
| Legal status | ℞ Prescription only |
| Routes | Oral |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Half-life | 1.5 hours |
| Excretion | Minor, renal and fecal |
| Identifiers | |
| CAS number | 7416-34-4  |
| ATC code | N05AE02 |
| PubChem | CID 23897 |
| IUPHAR ligand | 207 |
| DrugBank | DB01618 |
| ChemSpider | 22342 |
| UNII | RT3Y3QMF8N |
| KEGG | D08226 |
| ChEMBL | CHEMBL460 |
| Chemical data | |
| Formula | C16H24N2O2 |
| Mol. mass | 276.374 g/mol |
| SMILES
| |
| |
 (what is this?) (verify) | |
Molindone (Moban) is a therapeutic antipsychotic, used in the treatment of schizophrenia.[1] It works by blocking the effects of dopamine in the brain, leading to diminished psychoses. It is rapidly absorbed when taken by mouth.
It is sometimes described as a typical antipsychotic,[2] and sometimes described as an atypical antipsychotic.[3]
Molindone was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010. [4]
Adverse effects
The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.[3][5]
See also
References
- ↑ "molindone". F.A. Davis Company.
- ↑ Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother 6 (4): 198–204. doi:10.1016/j.amjopharm.2008.10.003. PMID 19028375.
- ↑ 3.0 3.1 Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). "Molindone for schizophrenia and severe mental illness". In Bagnall, Anne-Marie. Cochrane Database Syst Rev (1): CD002083. doi:10.1002/14651858.CD002083.pub2. PMID 17253473.
- ↑ http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm
- ↑ Allison DB, Mentore JL, Heo M et al. (1999). "Antipsychotic-induced weight gain: a comprehensive research synthesis". Am J Psychiatry 156 (11): 1686–96. PMID 10553730. Free full text
| ||||||||||||||||